Development Incyte News Today

WILMINGTON, Del. & WALTHAM, Mass.--(BUSINESS WIRE)--Dec 10, 2023--

- Trial met its primary endpoint across all dose cohorts with 74% of patients at the 0.3 mg/kg dose achieving a complete or partial response within the first six months of treatment - Data are...

– Sixteen oral presentations, as well as a plenary session and poster presentations, highlight new advances across eight of the Company’s medicines – Plenary Scientific Session will feature...